FDA Proposes Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring

Summary

The FDA is proposing new regulations for in vivo radiopharmaceuticals used in disease diagnosis and monitoring, in response to the FDAMA, to clarify evaluation and approval processes, and to establish criteria for safety and effectiveness under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act.